These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 21933990)

  • 21. American Urological Association (AUA) guideline on prostate cancer detection: process and rationale.
    Carter HB
    BJU Int; 2013 Sep; 112(5):543-7. PubMed ID: 23924423
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effective prostate cancer detection. Reduction of low-yield biopsies. Investigators of the American Cancer Society National Prostate Cancer Detection Project.
    Littrup PJ; Kane RA; Mettlin CJ; Murphy GP; Lee F; Toi A; Badalament R; Babaian R
    Cancer; 1994 Dec; 74(12):3146-58. PubMed ID: 7526969
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prostate cancer screening by prostate-specific antigen (PSA); a relevant approach for the small population of the Cayman Islands.
    Jyoti SK; Blacke C; Patil P; Amblihalli VP; Nicholson A
    Cancer Causes Control; 2018 Jan; 29(1):87-92. PubMed ID: 28918559
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Rates of prostate-specific antigen testing for early detection of prostate cancer: a first comparison of German results with current international data].
    Lebentrau S; May M; Maurer O; Schostak M; Lehsnau M; Ecke T; Al-Dumaini S; Hallmann S; Ahmed AM; Braun V; Haferkamp A; Bauer RM; Stief CG; Baumunk D; Hoschke B; Braun HP; Schäfer C; Hipp M; Maurer J; Braun KP; Wolff I; Brookman-May S; Gilfrich C
    Urologe A; 2014 May; 53(5):715-24. PubMed ID: 24700162
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of increasing the PSA cutoff to perform additional biomarker tests before prostate biopsy.
    Nordström T; Adolfsson J; Grönberg H; Eklund M
    BMC Urol; 2017 Oct; 17(1):92. PubMed ID: 28974201
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Economic Analysis of Prostate-Specific Antigen Screening and Selective Treatment Strategies.
    Roth JA; Gulati R; Gore JL; Cooperberg MR; Etzioni R
    JAMA Oncol; 2016 Jul; 2(7):890-8. PubMed ID: 27010943
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Structured Population-based Prostate-specific Antigen Screening for Prostate Cancer: The European Association of Urology Position in 2019.
    Gandaglia G; Albers P; Abrahamsson PA; Briganti A; Catto JWF; Chapple CR; Montorsi F; Mottet N; Roobol MJ; Sønksen J; Wirth M; van Poppel H
    Eur Urol; 2019 Aug; 76(2):142-150. PubMed ID: 31092338
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Cost-Utility Analysis of Prostate Cancer Screening in Australia.
    Keller A; Gericke C; Whitty JA; Yaxley J; Kua B; Coughlin G; Gianduzzo T
    Appl Health Econ Health Policy; 2017 Feb; 15(1):95-111. PubMed ID: 27757918
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-Effectiveness of the Stockholm3 Test and Magnetic Resonance Imaging in Prostate Cancer Screening: A Microsimulation Study.
    Hao S; Heintz E; Östensson E; Discacciati A; Jäderling F; Grönberg H; Eklund M; Nordström T; Clements MS
    Eur Urol; 2022 Jul; 82(1):12-19. PubMed ID: 35094896
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up.
    Andriole GL; Crawford ED; Grubb RL; Buys SS; Chia D; Church TR; Fouad MN; Isaacs C; Kvale PA; Reding DJ; Weissfeld JL; Yokochi LA; O'Brien B; Ragard LR; Clapp JD; Rathmell JM; Riley TL; Hsing AW; Izmirlian G; Pinsky PF; Kramer BS; Miller AB; Gohagan JK; Prorok PC;
    J Natl Cancer Inst; 2012 Jan; 104(2):125-32. PubMed ID: 22228146
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Implications of false-positive results for future cancer screenings.
    Taksler GB; Keating NL; Rothberg MB
    Cancer; 2018 Jun; 124(11):2390-2398. PubMed ID: 29682740
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement.
    ; Grossman DC; Curry SJ; Owens DK; Bibbins-Domingo K; Caughey AB; Davidson KW; Doubeni CA; Ebell M; Epling JW; Kemper AR; Krist AH; Kubik M; Landefeld CS; Mangione CM; Silverstein M; Simon MA; Siu AL; Tseng CW
    JAMA; 2018 May; 319(18):1901-1913. PubMed ID: 29801017
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of Accountable Care Organizations on Diagnostic Testing for Prostate Cancer.
    Luckenbaugh AN; Hollenbeck BK; Kaufman SR; Yan P; Herrel LA; Skolarus TA; Norton EC; Schroeck FR; Jacobs BL; Miller DC; Hollingsworth JM; Shahinian VB; Borza T
    Urology; 2018 Jun; 116():68-75. PubMed ID: 29630957
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Re: optimization of PSA screening policies: a comparison of the patient and societal perspectives.
    Penson DF
    J Urol; 2013 Feb; 189(2):529-30. PubMed ID: 23312159
    [No Abstract]   [Full Text] [Related]  

  • 35. Prostate cancer screening in Tyrol, Austria: experience and results.
    Horninger W; Reissigl A; Rogatsch H; Volgger H; Studen M; Klocker H; Bartsch G
    Eur Urol; 1999; 35(5-6):523-38. PubMed ID: 10325519
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Guideline of guidelines: prostate cancer screening.
    Loeb S
    BJU Int; 2014 Sep; 114(3):323-5. PubMed ID: 24981126
    [No Abstract]   [Full Text] [Related]  

  • 37. [Estimating standard performance measures of opportunistic screening for prostate cancer].
    Leoni M; Falcini F; Ravaioli A; Foca F; Andalò G; Benini F; Dal Pozzo C; Ricci R; Naldoni C; Bucchi L
    Epidemiol Prev; 2008; 32(6):285-93. PubMed ID: 19353962
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Simulation optimization of PSA-threshold based prostate cancer screening policies.
    Underwood DJ; Zhang J; Denton BT; Shah ND; Inman BA
    Health Care Manag Sci; 2012 Dec; 15(4):293-309. PubMed ID: 22302420
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Benefit, Harm, and Cost-effectiveness Associated With Magnetic Resonance Imaging Before Biopsy in Age-based and Risk-stratified Screening for Prostate Cancer.
    Callender T; Emberton M; Morris S; Pharoah PDP; Pashayan N
    JAMA Netw Open; 2021 Mar; 4(3):e2037657. PubMed ID: 33704474
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of low free to total PSA ratio in prostate cancer screening: detection rates, clinical and pathological findings in Brazilian men with serum PSA levels <4.0 ng/mL.
    Faria EF; Carvalhal GF; dos Reis RB; Tobias-Machado M; Vieira RA; Reis LO; Nogueira L; Machado RD; Freitas CH; Magnabosco WJ; Mauad EC; Carvalho AL
    BJU Int; 2012 Dec; 110(11 Pt B):E653-7. PubMed ID: 22892057
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.